Galenical formulations of organic compounds

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the p...

Full description

Saved in:
Bibliographic Details
Main Authors ALTENBURGER RALF, BOCK MICHAELA ANNA MARIA, BARGENDA NICOLE, MATHARU AMOL SINGH, KOWALSKI JAMES, GHOSH INDRAJIT, HIRSCH STEFAN, LOGGIA NICOLETTA, LAKSHMAN JAY PARTHIBAN, BUSS BRUNO, TAILLEMITE JULIEN, VIPPAGUNTA SUDHA, WOLF MARIERISTINE, TONG WEI-QIN, CURDY CATHERINE, KELLER PATRICE FRANCOIS, LI SHOUFENG, ADLER SABINE, KOCHHAR CHARU, WEN HONG, BABIOLE SAUNIER MAGGY
Format Patent
LanguageChinese
English
Published 18.08.2010
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.
Bibliography:Application Number: CN200880108860